MicroRNAs in melanoma biology

Advances in Experimental Medicine and Biology

Volumn 774, Issue , 2013, Pages 103-120

  Kunz, Manfred ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Melanoma; Non coding RNAs; Oncogenes; Protein degradation; Tumour development

Indexed keywords

DACARBAZINE; IPILIMUMAB; LET 7; MICRORNA; MICRORNA 10B; MICRORNA 143; MICRORNA 145; MICRORNA 146B 5P; MICRORNA 148; MICRORNA 150; MICRORNA 155; MICRORNA 182; MICRORNA 193A 3P; MICRORNA 193B; MICRORNA 200C; MICRORNA 211; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 23A; MICRORNA 23B; MICRORNA 28 3P; MICRORNA 28 5P; MICRORNA 342 3P; MICRORNA 342 5P; MICRORNA 455 3P; MICRORNA 497; SORAFENIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; LONG TERM SURVIVAL; MELANOMA; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; UPREGULATION; ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; REVIEW; SKIN TUMOR;

ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICRORNAS; SKIN NEOPLASMS;

MLCS; MLOWN;

EID: 84934438094     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-7-5590-1_6     Document Type: Article

References (90)

1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
2. Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. Elegans. Cell 75:855-862
3. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215-233
4. Grimson A, Farh KK-H, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27:91-105
5. Borneman AR, Leigh-Bell JA, Yu H, Bertone P, Gerstein M, Snyder M (2006) Target hub proteins serve as master regulators of development in yeast. Genes Dev 20:435-448
6. Liang H, Li W-H (2007) MicroRNA regulation of human protein protein interaction network. RNA 13:1402-1408
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834-838
8. Esquela-Kerscher A, Slack FJ (2006) Oncomirs -microRNAs with a role in cancer. Nat Rev Cancer 6:259-269
9. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-2261
10. Zhang W, Dahlberg JE, Tam W (2007) MicroRNAs in tumorigenesis. Am J Pathol 171:728-738
11. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ (2005) RAS is regulated by the let-7 microRNA family. Cell 120:635-647
12. Akao Y, Nakagawa Y, Naoe T (2006) let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29:903-906
13. Lopez-Serra P, Esteller M (2012) DNA methylationassociated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31:1609-1622
14. van Kouwenhove M, Kedde M, Agami R (2011) MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 11:644-656
15. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM (2005) A microRNA polycistron as a potential human oncogene. Nature 435:828-833
16. Mendell JT (2008) miRiad roles for the miR-17-92 cluster in development and disease. Cell 133:217-222
17. Mu P, Han Y-C, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A (2009) Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23:2806-2811
18. Garzon R, Croce CM (2008) MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 15:352-358
19. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J (2010) The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 84:1-16
20. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 103:7024-7029
21. Beitzinger M, Peters L, Zhu JY, Kremmer E, Meister G (2007) Identification of human microRNA targets from isolated argonaute protein complexes. RNA Biol 4:76-84
22. Weinstein IB, Joe A, Felsher D (2008) Oncogene addiction. Cancer Res 68:3077-3080
23. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
24. Medina PP, Nolde M, Slack FJ (2010) OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467:86-90
25. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682-688
26. Ma L, Weinberg RA (2008) Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet 24:448-456
27. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451:147-152
28. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355:51-65
29. Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27:3-9
30. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
31. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho K-H, Aiba S, Bröcker E-B, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147
32. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AMM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
33. Davies MA, Samuels Y (2010) Analysis of the genome to personalize therapy for melanoma. Oncogene 29:5545-5555
34. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman R-A, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-2334
35. Coleman ML, Marshall CJ, Olson MF (2004) RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 5:355-366
36. Sherr C (2004) Principles of tumor suppression. Cell 116:235-246
37. Malumbres M, Barbacid M (2005) Mammalian cyclindependent kinases. Trends Biochem Sci 30:630-641
38. Chudnovsky Y, Khavari PA, Adams AE (2005) Melanoma genetics and the development of rational therapeutics. J Clin Invest 115:813-824
39. Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L (2003) Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 22:5055-5059
40. Kabbarah O, Chin L (2006) Advances in malignant melanoma: genetic insights from mouse and man. Front Biosci 11:928-942
41. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-552
42. Yasumoto K, Yokoyama K, Shibata K, Tomita Y, Shibahara S (1833) Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol 1995:15
43. Wellbrock C, Marais R (2005) Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 170:703-708
44. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122
45. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687-701
46. Sondak VK, Han D, Deneve J, Kudchadkar R (2011) Current and planned multicenter trials for patients with primary or metastatic melanoma. J Surg Oncol 104:430-437
47. Rubin KM, Lawrence DP (2009) Your patient with melanoma: staging, prognosis, and treatment. Oncology (Williston Park, NY) 23:13-21
48. Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AMM, Espinosa E, Hauschild A, Quirt I, Robert C, Schadendorf D (2009) Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 20(Suppl 6):vi35-40
49. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
50. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee M-K, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977
51. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinasedead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221
52. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
53. Robert C, Thomas L, Bondarenko I, O'Day S, JW MD, Garbe C, Lebbe C, Baurain J-F, Testori A, Grob J-J, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen T-T, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
54. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-1070
55. Mueller DW, Bosserhoff AK (2009) Role of miRNAs in the progression of malignant melanoma. Br J Cancer 101:551-556
56. Mueller DW, Bosserhoff A-K (2010) The evolving concept of "melano-miRs"-microRNAs in melanomagenesis. Pigment Cell Melanoma Res 23:620-626
57. Bar-Eli M (2011) Searching for the "melano-miRs": miR-214 drives melanoma metastasis. EMBO J 30:1880-1881
58. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O'brien-Jenkins A, Katsaros D, Hatzigeorgiou A, Gimotty PA, Weber BL, Coukos G (2006) MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103:9136-9141
59. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67:2456-2468
60. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67:7713-7722
61. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M (2008) MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 18:549-557
62. Müller DW, Bosserhoff A-K (2008) Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 27:6698-6706
63. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284
64. Flørenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000) Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in super ficial melanoma. Clin Cancer Res 6:3614-3620
65. Flørenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001) Cyclin A expression in super ficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195:530-536
66. Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L, Acuña MJ, Pajares R, Martínez-Tello FJ, Hortelano CM, Piris MA, Rodríguez-Peralto JL (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164:193-203
67. Sauter ER, Yeo U-C, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC (2002) Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62:3200-3206
68. Sotillo R, García JF, Ortega S, Martin J, Dubus P, Barbacid M, Malumbres M (2001) Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci USA 98:13312-13317
69. Tessari MA, Gostissa M, Altamura S, Sgarra R, Rustighi A, Salvagno C, Caretti G, Imbriano C, Mantovani R, Del Sal G, Giancotti V, Manfioletti G (2003) Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 23:9104-9116
70. Lee YS, Dutta A (2007) The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21:1025-1030
71. Ha flidadóttir BS, Bergsteinsdóttir K, Praetorius C, Steingrímsson E (2010) miR-148 regulates Mitf in melanoma cells. PLoS One 5:e11574
72. Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA (2008) MicroRNA-137 targets microphthalmiaassociated transcription factor in melanoma cell lines. Cancer Res 68:1362-1368
73. Philippidou D, Schmitt M, Moser D, Margue C, Nazarov PV, Muller A, Vallar L, Nashan D, Behrmann I, Kreis S (2010) Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 70:4163-4173
74. Peter ME (2009) let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8:843-852
75. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ (2007) Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 67:7972-7976
76. Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, Chen P-H, Li S, Fletcher AL, Yokoyama S, Scott KL, Garraway LA, Song JS, Granter SR, Turley SJ, Fisher DE, Novina CD (2010) Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 40:841-849
77. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 106:1814-1819
78. Huynh C, Segura MF, Gaziel-Sovran A, Menendez S, Darvishian F, Chiriboga L, Levin B, Meruelo D, Osman I, Zavadil J, Marcusson EG, Hernando E (2011) Efficient in vivo microRNA targeting of liver metastasis. Oncogene 30:1481-1488
79. Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, McCarthy JJ (2001) Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 19:568-576
80. Mazar J, DeYoung K, Khaitan D, Meister E, Almodovar A, Goydos J, Ray A, Perera RJ (2010) The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One 5:e13779
81. Weaver AK, Bomben VC, Sontheimer H (2006) Expression and function of calcium-activated potassium channels in human glioma cells. Glia 54:223-233
82. Nazarian RM, Prieto VG, Elder DE, Duncan LM (2010) Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol 37(Suppl 1):41-47
83. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, Valtieri M, Calin GA, Liu C-G, Sorrentino A, Croce CM, Peschle C (2005) MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 102:18081-18086
84. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, Felli N, Mattia G, Petrini M, Colombo MP, Peschle C, Carè A (2008) The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68:2745-2754
85. Felicetti F, Bottero L, Felli N, Mattia G, Labbaye C, Alvino E, Peschle C, Colombo MP, Carè A (2004) Role of PLZF in melanoma progression. Oncogene 23:4567-4576
86. Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, Pinatel E, Stadler MB, Provero P, Bernengo MG, Osman I (2011) Taverna D: microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 30:1990-2007
87. Bar-Eli M (2001) Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 14:78-85
88. Segura MF, Belitskaya-Lévy I, Rose AE, Zakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Osman I, Hernando E (2010) Melanoma microRNA signature predicts post-recurrence survival. Clin Cancer Res 16:1577-1586
89. Levati L, Alvino E, Pagani E, Arcelli D, Caporaso P, Bondanza S, Di Leva G, Ferracin M, Volinia S, Bonmassar E, Croce CM, D'Atri S (2009) Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol 35:393-400
90. Caramuta S, Egyházi S, Rodolfo M, Witten D, Hansson J, Larsson C, Lui W-O (2010) MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 130:2062-2070